Who are FFP+HDMP+Rituximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ffp-hdmp-rituximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

FFP+HDMP+Rituximab — Competitive Intelligence Brief

FFP+HDMP+Rituximab (FFP+HDMP+Rituximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination immunosuppressive therapy (corticosteroid + monoclonal antibody + blood product). Area: Immunology / Hematology.

phase 3 Combination immunosuppressive therapy (corticosteroid + monoclonal antibody + blood product) CD20 (rituximab component); glucocorticoid receptor (HDMP component) Immunology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

FFP+HDMP+Rituximab (FFP+HDMP+Rituximab) — The First Affiliated Hospital with Nanjing Medical University. This combination therapy uses fresh frozen plasma (FFP) and high-dose methylprednisolone (HDMP) with rituximab to suppress autoimmune responses by depleting B cells and reducing inflammatory mediators.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FFP+HDMP+Rituximab TARGET	FFP+HDMP+Rituximab	The First Affiliated Hospital with Nanjing Medical University	phase 3	Combination immunosuppressive therapy (corticosteroid + monoclonal antibody + blood product)	CD20 (rituximab component); glucocorticoid receptor (HDMP component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination immunosuppressive therapy (corticosteroid + monoclonal antibody + blood product) class)

The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FFP+HDMP+Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/ffp-hdmp-rituximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab